BioSpace News Archive

A bipartisan coalition mostly made up of former government officials is promoting a $46 billion plan to “reopen the economy.” In a letter sent to congressional leaders, the coalition wrote that the key is to “test, trace, and self-isolate.” The plan calls for hiring 180,000 new contact tracers, “until a vaccine for COVID-19 is on the market.” The group recommends that “primary care providers become a referral source for testing and contact tracing.”

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, successfully closed the acquisition of selected life science businesses of Danaher Corporation.

Organizations partner to deliver trusted point-of-care education amid global pandemic

Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2020 financial results after the close of market on Thursday, May 7, 2020

With the world’s attention focused on the response to COVID-19, the Melanoma Research Alliance (MRA) knows that long after this pandemic has ended, melanoma research will still be urgently needed.

Synaptive Medical, a leader in robotic surgical visualization, announced today the company has secured clearance from the Food and Drug Administration (FDA) for its superconducting, head magnetic resonance imaging (MRI) technology, Evry™.

VIVEX Biologics, Inc., a leading regenerative medicine company specializing in the development of naturally sourced treatment options, today announced that the initial clinical trial results of VIVEX’s VAST Trial evaluating VIA® Disc were published in the peer-reviewed journal The International Journal of Spine Surgery.

Junshi Biosciences (HKEX: 1877), today announced that the China National Medical Products Administration (NMPA) has accepted a supplemental New Drug Application (sNDA) for toripalimab as a treatment for patients with recurrent/metastatic nasopharyngeal carcinoma (NPC) who failed at least two lines of systemic therapy.

Healthcare workers have been on the frontlines of responding to the COVID-19 pandemic, making them particularly vulnerable to contracting the virus.

NANOBIOTIX, a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced its unaudited revenues for the first quarter of 2020.